Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Ban Triclosan, House Democrats Urge

This article was originally published in The Tan Sheet

Executive Summary

More Democratic House members are calling for a ban on triclosan use in personal-care products with a letter to FDA Commissioner Margaret Hamburg.

You may also be interested in...



Lindane Ban Request Presents Chance To Promote Natural Lice Solutions

The insecticide agent lindane used in lice treatments is hazardous, ineffective and bad for the environment, Rep. Markey says in a letter to FDA. Growing criticism of the use of harsh chemicals could create opportunities for natural solutions to grow sales.

Lindane Ban Request Presents Chance To Promote Natural Lice Solutions

The insecticide agent lindane used in lice treatments is hazardous, ineffective and bad for the environment, Rep. Markey says in a letter to FDA. Growing criticism of the use of harsh chemicals could create opportunities for natural solutions to grow sales.

Canada To Push For Reduced Triclosan Use In Personal Care Products

A draft safety assessment in Canada says triclosan exposure through the use of personal care products poses little health risk to consumers. But Canadian authorities also find the antimicrobial may pose some environmental risks and may be no more effective in products than available alternatives.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel